Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Prepaid Assets (2017 - 2025)

Historic Prepaid Assets for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $34.4 million.

  • Denali Therapeutics' Prepaid Assets rose 654.89% to $34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.4 million, marking a year-over-year increase of 654.89%. This contributed to the annual value of $32.1 million for FY2024, which is 836.77% up from last year.
  • Per Denali Therapeutics' latest filing, its Prepaid Assets stood at $34.4 million for Q3 2025, which was up 654.89% from $35.8 million recorded in Q2 2025.
  • Denali Therapeutics' Prepaid Assets' 5-year high stood at $60.7 million during Q1 2025, with a 5-year trough of $15.1 million in Q3 2021.
  • Moreover, its 5-year median value for Prepaid Assets was $32.5 million (2022), whereas its average is $32.6 million.
  • As far as peak fluctuations go, Denali Therapeutics' Prepaid Assets surged by 18432.84% in 2022, and later plummeted by 2742.73% in 2023.
  • Denali Therapeutics' Prepaid Assets (Quarter) stood at $30.6 million in 2021, then grew by 17.98% to $36.1 million in 2022, then fell by 17.94% to $29.6 million in 2023, then increased by 8.37% to $32.1 million in 2024, then grew by 7.13% to $34.4 million in 2025.
  • Its last three reported values are $34.4 million in Q3 2025, $35.8 million for Q2 2025, and $60.7 million during Q1 2025.